title: [Dysmorphophobia (body dysmorphic disorder)].
abstract: This article reviews the historical and terminological origins of dysmorphophobia from Herodotus to today. It explains the differences pointed out by many authors, including the DSM-III-R, between body dismorphic disorder and delusional disorder somatic type, which are referred to as monosymptomatic hypochondriacal psychoses in Europe. Epidemiological data, clinical characteristics and outcome are discussed. Explicative theories and neurobiological, developmental and analytical aspects of body image are presented. The association between body dismorphic disorder and other disorders is analyzed, and treatment possibilities are discussed. The authors suggest that body dismorphic disorder be classified with obsessive compulsive disorder, whatever the intensity of symptomatology, rather than with somatoform or delusional disorder, and treated with serotonin uptake inhibitors or neureptics that have been proven to be effective for the treatment of this disorder, such as pimozide.
authors.affiliation: Département de psychiatrie, Hôpital de l'Enfant Jésus, Québec.
authors.forename: M J
authors.initials: MJ
authors.lastname: Filteau
authors.forename: E
authors.initials: E
authors.lastname: Pourcher
authors.forename: P
authors.initials: P
authors.lastname: Baruch
authors.forename: R H
authors.initials: RH
authors.lastname: Bouchard
authors.forename: P
authors.initials: P
authors.lastname: Vincent
mesh_terms: D001828:Body Image; D003702:Delusions / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D010868:Pimozide / Q000627:therapeutic use; D015995:Prevalence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D009626:Terminology as Topic
chemical_list: D010868:Pimozide; D017367:Selective Serotonin Reuptake Inhibitors
vernacular_title: La dysmorphophobie (trouble dysmorphique physique).